$75 Million

KemPharm

Convertible Debt

Sole Bookrunner, February 2016

KemPharm
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LATTM (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LATTM technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm’s prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm’s co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen

More Like This

Jan 2021
$69 Million

Convertible Notes Restructuring

Exclusive Financial Advisor

View Details >
Nov 2020
$197 Million
Tilray Logo

Convertible Notes Exchange

Exclusive Financial Advisor

View Details >
Nov 2020
$1.15 Billion

Convertible Debt

Co-Manager

View Details >